In vitro and in vivo characteristics of celecoxib in situ formed suspensions for intra-articular administration

Journal of Pharmaceutical Sciences

Volumn 100, Issue 10, 2011, Pages 4330-4337

  Larsen, Susan Weng ^a   Frost, Anna Buus ^a   Østergaard, Jesper ^a   Thomsen, Maj Halling ^b   Jacobsen, Stine ^b   Skonberg, Christian ^a   Hansen, Steen Honoré ^a   Jensen, Henrik Elvang ^b   Larsen, Claus ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Controlled release; Formulation vehicle; In vitro models; Injectables; Precipitation; Solid state; Suspensions

Indexed keywords

CELECOXIB; MACROGOL; PHOSPHATE BUFFERED SALINE; BUFFER; CYCLOOXYGENASE 2 INHIBITOR; DELAYED RELEASE FORMULATION; MACROGOL DERIVATIVE; PYRAZOLE DERIVATIVE; SOLUTION AND SOLUBILITY; SULFONAMIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG MEGADOSE; DRUG RELEASE; HORSE; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PARTICLE SIZE; PH; SYNOVIAL FLUID; WRIST; X RAY POWDER DIFFRACTION; ANIMAL; BLOOD; CHEMISTRY; CRYSTALLIZATION; DELAYED RELEASE FORMULATION; DRUG STABILITY; INTRAARTICULAR DRUG ADMINISTRATION; JOINT; MEDICINAL CHEMISTRY; METABOLISM; PHARMACEUTICS; POWDER DIFFRACTION; PROCEDURES; SOLUBILITY; SOLUTION AND SOLUBILITY; TISSUE DISTRIBUTION; X RAY CRYSTALLOGRAPHY;

ANIMALS; BUFFERS; CHEMISTRY, PHARMACEUTICAL; CRYSTALLIZATION; CRYSTALLOGRAPHY, X-RAY; CYCLOOXYGENASE 2 INHIBITORS; DELAYED-ACTION PREPARATIONS; DRUG STABILITY; HORSES; HYDROGEN-ION CONCENTRATION; INJECTIONS, INTRA-ARTICULAR; JOINTS; PHARMACEUTICAL SOLUTIONS; POLYETHYLENE GLYCOLS; POWDER DIFFRACTION; PYRAZOLES; SOLUBILITY; SULFONAMIDES; TECHNOLOGY, PHARMACEUTICAL; TISSUE DISTRIBUTION;

EID: 80052269663     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22630     Document Type: Article

References (23)

1. Larsen C, Østergaard J, Larsen SW, Jensen H, Jacobsen S, Lindegaard C, Andersen PH. 2008. Intra-articular depot formulation principles: Role in the management of postoperative pain and arthritic disorders. J Pharm Sci 97:4622-4654.
2. Frost AB, Larsen F, Larsen SW, Østergaard J, Thomsen MH, Stürup S, Andersen PH, Larsen C. 2010. The pharmacokinetics of the weakly protein-bound anionic compound diatrizoate in serum and synovial fluid of the horse. Pharm Res 27:143-150.
3. Packhaeuser CB, Schnieders J, Oster CG, Kissel T. 2004. In situ forming parenteral drug delivery systems: An overview. Eur J Pharm Biopharm 58:445-455.
4. Sartor O. 2003. Eligard: Leuprolide acetate in a novel sustained-release delivery system. Urology 61 (Suppl 2A):25-31.
5. Mills ML, Rush BR, St Jean G, Gaughan EM, Mosier D, Gibson E, Freeman L. 2000. Determination of synovial fluid and serum concentrations, and morphologic effects of intraarticular ceftiofur sodium in horses. Vet Surg 29:398-406.
6. Frampton JE, Keating GM. 2007. Celecoxib: A review of its use in the management of arthritis and acute pain. Drugs 67:2433-2472.
7. Dibbern HW, Wirbitzki E. 1983. Alternative technique for the determination of drug release from hydrophobic matrix particularly suppositories. Pharm Ind 45:985-990.
8. Pedersen BT, Østergaard J, Larsen SW, Larsen C. 2005. Characterization of the rotating dialysis cell as an in vitro model potentially useful for simulation of the pharmacokinetic fate of intra-articularly administered drugs. Eur J Pharm Sci 25:73-79.
9. Seedher N, Bhatia S. 2003. Solubility enhancement of Cox-2 inhibitors using various solvent systems. AAPS Pharm Sci Tech 4:E33.
10. Strickley RG. 2004. Solubilizing excipients in oral and injectable formulations. Pharm Res 21:201-230.
11. Dev RV, Rekha KS, Vyas K, Mohanti SB, Kumar PR, Reddy GO. 1999. Celecoxib, a COX-II inhibitor. Acta Crystallogr C55:IUC9900161.
12. Lu GW, Hawley M, Smith M, Geiger BM, Pfund W. 2006. Characterization of a novel polymorphic form of celecoxib. J Pharm Sci 95:305-317.
13. Chawla G, Gupta P, Thilagavathi R, Chakraborti AK, Bansal AK. 2003. Characterization of solid-state forms of celecoxib. Eur J Pharm Sci 20:305-317.
14. Ferro LJ, Miayake PJ. 2009. Polymorphic crystalline forms of celecoxib. Patent US7476744.
15. Larsen SW, Østergaard E, Poulsen SV, Schulz B, Larsen C. 2007. Diflunisal salts of bupivacaine, lidocaine, and morphine: Use of the common ion effect for prolonging the release of bupivacaine from mixed salt suspensions in an in vitro dialysis model. Eur J Pharm Sci 31:172-179.
16. Larsen SW, Frost AB, Østergaard J, Marcher H, Larsen C. 2008. On the mechanism of drug release from oil suspensions in vitro using local anesthetics as model drug compounds. Eur J Pharm Sci 34:37-44.
17. Larsen SW, Jessen MNB, Østergaard J, Larsen C. 2008. Assessment of drug release from oil depot formulations using an in vitro model: Potential applicability in accelerated release testing. Drug Dev Ind Pharm 34:297-304.
18. Parshad H, Frydenvang K, Liljefors T, Cornett C, Larsen C. 2003. Assessment of drug salt release from solutions, suspensions, and in situ suspensions using a rotating dialysis cell. Eur J Pharm Sci 19:263-272.
19. Pedersen BT, Larsen SW, Østergaard J, Larsen C. 2008. In vitro assessment of lidocaine release from aqueous and oil solutions and from preformed and in situ formed aqueous and oil suspensions. Parenteral depots for intra-articular administration. Drug Deliv 15:23-30.
20. Østergaard J, Larsen SW, Parshad H, Larsen C. 2005. Bupivacaine salts of diflunisal and other aromatic hydroxycarboxylic acids: Aqueous solubility and release characteristics from solutions and suspensions using a rotating dialysis cell model. Eur J Pharm Sci 26:280-287.
21. Brouwers J, Brewster ME, Augustijns P. 2009. Supersaturating drug delivery systems: The answer to solubility-limited oral bioavailability? J Pharm Sci 98:2549-2572.
22. Guzman HR, Tawa M, Zhang Z, Ratanabanangkoon P, Shaw P, Gardner CR, Chen H, Moreau JP, Almarsson O, Remenar JF. 2007. Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations. J Pharm Sci 96:2686-2702.
23. Davies NM, McLachlan AJ, Day RO, Williams KM. 2000. Clinical pharmacokinetics and pharmacodynamics of celecoxib: A selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet 38:225-242.